Jaguar Animal Health (NASDAQ:JAGX – Get Free Report) and ProKidney (NASDAQ:PROK – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, dividends, earnings, institutional ownership and analyst recommendations.
Earnings and Valuation
This table compares Jaguar Animal Health and ProKidney”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Jaguar Animal Health | $29.54 million | 0.07 | -$53.43 million | ($591.92) | -0.01 |
| ProKidney | $890,000.00 | 627.88 | -$68.99 million | ($0.53) | -3.49 |
Analyst Recommendations
This is a summary of current ratings for Jaguar Animal Health and ProKidney, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Jaguar Animal Health | 1 | 0 | 0 | 0 | 1.00 |
| ProKidney | 2 | 1 | 4 | 1 | 2.50 |
ProKidney has a consensus target price of $7.40, suggesting a potential upside of 300.00%. Given ProKidney’s stronger consensus rating and higher possible upside, analysts plainly believe ProKidney is more favorable than Jaguar Animal Health.
Profitability
This table compares Jaguar Animal Health and ProKidney’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Jaguar Animal Health | -169.04% | -1,194.94% | -115.55% |
| ProKidney | -8,131.50% | N/A | -21.39% |
Risk and Volatility
Jaguar Animal Health has a beta of 0.01, meaning that its stock price is 99% less volatile than the S&P 500. Comparatively, ProKidney has a beta of 1.65, meaning that its stock price is 65% more volatile than the S&P 500.
Institutional & Insider Ownership
12.0% of Jaguar Animal Health shares are held by institutional investors. Comparatively, 51.6% of ProKidney shares are held by institutional investors. 2.1% of Jaguar Animal Health shares are held by insiders. Comparatively, 39.8% of ProKidney shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
ProKidney beats Jaguar Animal Health on 11 of the 15 factors compared between the two stocks.
About Jaguar Animal Health
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
About ProKidney
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Receive News & Ratings for Jaguar Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.
